Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2015 | 12-2014 | 09-2014 | 06-2014 | 03-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,254 | 4,410 | 16,589 | -20,386 | -9,313 |
| Depreciation Amortization | 132 | 3,221 | 995 | 277 | 144 |
| Income taxes - deferred | N/A | -989 | -228 | -1 | N/A |
| Accounts receivable | -43 | 2,770 | -38,788 | 1,411 | 2,062 |
| Other Working Capital | -1,815 | 2,253 | -39,314 | -866 | -1,376 |
| Other Operating Activity | 1,098 | 2,061 | 42,856 | 1,585 | -832 |
| Operating Cash Flow | $-10,882 | $13,726 | $-17,890 | $-17,980 | $-9,315 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -51 | -571 | -199 | 8 | 36 |
| Sale Of Investment | N/A | 2,400 | N/A | N/A | N/A |
| Investing Cash Flow | $-51 | $1,829 | $-199 | $8 | $36 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 61 | 37,887 | 37,459 | 37,459 | 37,455 |
| Financing Cash Flow | $61 | $37,887 | $37,459 | $37,459 | $37,455 |
| Beginning Cash Position | 119,302 | 65,860 | 65,860 | 65,860 | 65,860 |
| End Cash Position | 108,430 | 119,302 | 85,230 | 85,347 | 94,036 |
| Net Cash Flow | $-10,872 | $53,442 | $19,370 | $19,487 | $28,176 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,882 | 13,726 | -17,890 | -17,980 | -9,315 |
| Capital Expenditure | -53 | -714 | -327 | -68 | -10 |
| Free Cash Flow | -10,935 | 13,012 | -18,217 | -18,048 | -9,325 |